Singapore Medical Device Classification: Classes A to D

1. Key takeaways

Singapore applies a four-tier risk classification: Class A (low risk), Class B (low to moderate risk), Class C (moderate to high risk) and Class D (high risk), consistent with the classification principles of GHTF/IMDRF and the ASEAN Medical Device Directive (AMDD). The determination is made under GN-13 R2.1 (general medical devices) and GN-14 R3 (in vitro diagnostic medical devices), and can be cross-checked against the GL-06 R2 product classification guide. Class A devices are exempt from product registration, while Class B/C/D devices must be registered. Because the classification decides the pathway, and the pathway decides both cost and review time, classification is the first gate every Singapore project must pass through.

• Classification is determined rule-by-rule under GN-13 R2.1 for general devices and GN-14 R3 for IVDs, with GL-06 R2 as a cross-validation tool.
• Class A is exempt from registration and is handled by product notification; Class B/C/D require registration under GN-15 R15 Section 3.
• IVDs follow a fundamentally different classification logic from general devices and must never be assessed using GN-13 rules.
• Software has its own classification dimensions, driven by the impact of the information on clinical decisions rather than invasiveness.

2. Legal basis

The instruments below constitute the classification framework, from the primary guidance documents through to the registration consequence that each class carries under GN-15.

To make the classes concrete, the following mapping shows the risk level and typical product examples for each class of general medical device. The examples are indicative anchors drawn from the classification framework; the class of any specific product must still be determined against the rules for that product’s own intended use.

3. Expert insights

Insight 1: The cost of a classification error is a triple loss — rejection, sunk fees and a reset timeline. Classification determines the pathway, and the pathway determines fees and review duration. If a product that should be Class C is submitted as Class B, HSA will require reclassification and a fresh submission; the review fees already paid are non-refundable and the review clock resets to zero. In our front-end assessments we treat classification as the first gate, applying the GN-13/GN-14 rules item by item and then cross-validating the result with GL-06 R2. Only after the classification is defended in writing do we move on to pathway selection and fee planning, because every downstream decision inherits the classification conclusion.

Insight 2: IVDs must not be assessed using the general device rules. This is the most common technical error. IVDs follow GN-14 R3, whose classification logic is built on the purpose of the test, the target analyte and the setting of use — a logic entirely different from the invasiveness, duration of use and energy supply logic of general devices. In addition, HSA maintains dedicated guidance for next generation sequencing (NGS) and the GL-08 R2 guidance on laboratory-developed tests (LDTs) (September 2025), so portfolios touching these specialised areas need additional cross-checking. Teams that reuse a single classification memo across reagent and instrument lines, or that import conclusions from other jurisdictions without mapping them to the Singapore rules, systematically produce the wrong answers here.

Insight 3: Software has an independent classification dimension. GL-07 R2 (July 2025) provides risk classification rules for SAMD-CDSS, and GL-04 R4 provides the full life cycle regulatory approach for SaMD. Software is not classified by invasiveness; the drivers are the degree to which the information affects clinical decisions and the seriousness of the condition being diagnosed or treated. A mobile application with no therapeutic claim and a clinical decision support tool advising on the management of a serious condition may look similar on the surface, yet sit in entirely different classes with entirely different submission burdens.

Insight 4: HSA holds the final interpretive authority on classification, so ask when in doubt. HSA offers pre-market consultation (pre-submission consultation at S$210). For a high-value product line, spending S$210 to lock in the classification position is far better than gambling on a pathway that may turn out to be wrong. The consultation answer also creates a documented basis for the classification decision that can be referenced in the dossier and in later change assessments.

4. Practical recommendations

• Use a three-step determination method: (1) apply the GN-13 (or GN-14) rules item by item; (2) cross-validate with GL-06 R2; (3) check the actual classification of comparable registered products in SMDR.
• Use SMDR for benchmarking: search the Singapore Medical Device Register for the classification outcomes of comparable competing products as third-party corroboration of your own determination.
• Record the classification conclusion in the project file: fix the determination process and its basis in writing for later reference in pathway selection, cost estimation and change management.
• Re-determine classification on licence renewal or portfolio expansion: changes in intended use and technical changes can both trigger a change in class; never carry forward an old conclusion without review.

5. Verification checklist

• □ Classification has been determined rule-by-rule under GN-13 R2.1 or GN-14 R3
• □ The result has been cross-validated with GL-06 R2
• □ Software products have been assessed with reference to GL-04 R4 / GL-07 R2
• □ Comparable products have been searched in SMDR for benchmarking
• □ The classification conclusion has been recorded in the project file
• □ Projects with residual doubt have been assessed for HSA pre-submission consultation

Regulatory information verified as of: 26 October 2026

Source level: Tier 2 (GN-13 R2.1, GN-14 R3, GL-06 R2, GL-07 R2, GN-15 R15)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com